Additional file 1: of Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, and 10 mg/kg for all grades and high grade. Figures S8 to S27 Organ-specific irAEs (endocrine, skin, gastrointestinal, and hepatic) for ipilimumab all dosage, 3 mg/kg, and 10 mg/kg and Tremelimumab, for all grades and high grade. Figures S28 to S31 Risk ratio of developing irAEs with ipilimumab at 10 mg/kg comparing with 3 mg/kg for organ-specific irAEs (gastrointestinal, skin, endocrine, and hepatic). Table S2 General characteristics of patients receiving anti-CTLA4 antibodies described in case reports. Table S3 Organ-specific irAEs. Table S4 Quality assessment. (DOCX 12329 kb

Additional file 1: of Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review

Presenting search strategies. (DOC 201 kb